Dextera Surgical Inc. (NASDAQ:DXTR) – Equities research analysts at Wedbush lowered their FY2018 earnings estimates for shares of Dextera Surgical in a report released on Tuesday. Wedbush analyst Levy. T now forecasts that the medical instruments supplier will post earnings of ($0.21) per share for the year, down from their prior estimate of ($0.20). Wedbush currently has a “Outperform” rating and a $0.70 target price on the stock. Wedbush also issued estimates for Dextera Surgical’s FY2019 earnings at ($0.22) EPS.

A number of other brokerages also recently commented on DXTR. Zacks Investment Research raised shares of Dextera Surgical from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Ladenburg Thalmann Financial Services assumed coverage on shares of Dextera Surgical in a research report on Wednesday, August 16th. They issued a “buy” rating and a $0.80 price objective for the company.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at

Dextera Surgical (NASDAQ:DXTR) last issued its quarterly earnings data on Tuesday, August 8th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.29). The company had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $1.03 million.

Several institutional investors and hedge funds have recently made changes to their positions in DXTR. Perkins Capital Management Inc. bought a new position in shares of Dextera Surgical in the 2nd quarter valued at about $100,000. Virtu KCG Holdings LLC grew its position in shares of Dextera Surgical by 1,380.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 369,918 shares of the medical instruments supplier’s stock valued at $111,000 after acquiring an additional 344,933 shares during the period. Finally, Broadfin Capital LLC grew its position in shares of Dextera Surgical by 64.7% in the 2nd quarter. Broadfin Capital LLC now owns 987,520 shares of the medical instruments supplier’s stock valued at $296,000 after acquiring an additional 388,080 shares during the period. 6.58% of the stock is owned by institutional investors.

Dextera Surgical Company Profile

Dextera Surgical Inc, formerly Cardica, Inc, designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

Earnings History and Estimates for Dextera Surgical (NASDAQ:DXTR)

Receive News & Stock Ratings for Dextera Surgical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical Inc. and related stocks with our FREE daily email newsletter.